INR — Calibration of the Therapeutic Range

  • Leon Poller


The prothrombin time (PT) is the most important coagulation test. After many years of disagreement, an international system of standardisation has been accepted. Fifty years after Quick1 described the PT to detect coagulation defects, the control of oral anticoagulant therapy is still largely dependent on the test. Many modifications to the original technique have been introduced, and new methods have been developed specifically, e.g. the prothrombin and proconvertin test (P and P test),2 and the Throm-botest,3 but their application has been limited in comparison. Clinical reports of anticoagulant trials, giving no details of the PT method are still published.(e,g.4)


Deep Vein Thrombosis International Normalise Ratio Therapeutic Range Oral Anticoagulant Oral Anticoagulant Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. J. Quick, The prothrombin in haemophilia and in obstructive jaundice, J. Biol. Chem. 109:73–74 (1935).Google Scholar
  2. 2.
    P. A. Owren and K. Aas, The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin, Scand. J. Clin. Lab. Invest. 3:201–208 (1951).PubMedCrossRefGoogle Scholar
  3. 3.
    P.A. Owren, Thrombotest: a new method for controlling anticoagulant therapy, Lancet ii:754–758 (1959).CrossRefGoogle Scholar
  4. 4.
    C. W. Francis, V. J. Marder, E. C. McCollister, and S. Yankoolbodi, Two step warfarin therapy, J. Am. Med. Assoc. 249:374–378 (1983).CrossRefGoogle Scholar
  5. 5.
    L. Poller and D. A. Taberner, Dosage and Control of oral anticoag- ulants, An international survey, Br. J. Haematol. 51:479 (1982).PubMedCrossRefGoogle Scholar
  6. 6.
    L. Poller, Standardisation of anticoagulant treatment: The Manchester Regional Thromboplastin Scheme, Br. Med. J. 2:565–566 (1964).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Biggs, Report on the standardisation of the one stage prothrombin time for the control of anticoagulant therapy, in: “Genetics and the interaction of blood clotting factors,” R. B. Hunter, I. S. Wright and F. Koller, eds., Thrombosis et Diathesis Haemorrhagica Supplement 17:303–327 (1965).Google Scholar
  8. 8.
    L. Poller, The British Comparative Thromboplastin: the use of the national thromboplastin reagent for uniformity of laboratory control of oral anticoagulants and expression of results, Assoc. Clin. Pathol., Broadsheet No.71 (1970).Google Scholar
  9. 9.
    J. B. Miale and J. W. Kent, Standardisation of the therapeutic range for oral anticoagulants based on standard reference plasmas, Am. J. Clin. Pathol., 60:453–457 (1972).Google Scholar
  10. 10.
    T. B. L. Kirkwood, Calibration of reference thromboplastins, Thromb Haemost. (Stuttgart) 49:238–244 (1983).PubMedGoogle Scholar
  11. 11.
    J. Hermans, A. M. P. H. van den Besselaar, E. A. Loeliger, and E. A. van der Veld, A collaborative calibration study of reference materials for thromboplastins, Thromb. Haemost. (Stuttgart) 50:3: 712–717 (1983).PubMedGoogle Scholar
  12. 12.
    J. M. Thomson, J. A. Tomenson, and L. Poller, The calibration of the Second Primary International Reference Preparation for Thromboplastin (Thromboplastin, human, plain, coded BCT/253), Thromb. Haemost. (Stuttgart) 52:336–342 (1984).PubMedGoogle Scholar
  13. 13.
    J. M. Thomson, K. V. Darby, and L. Poller, Calibration of BCT/44I the ICSH Reference Preparation for Thromboplastin, Thromb. Haemost. (Stuttgart) 55:379–382 (1986).PubMedGoogle Scholar
  14. 14.
    J. A. Tomenson, A statistician’s independent evaluation, in; “Thromboplastin calibration and oral anticoagulant control,” A. M. H. P. van den Besselaar, H. R. Gralnick, and S. M. Lewis, eds., Martinus Nijhoff, The Hague (1984).Google Scholar
  15. 15.
    R. Hull, J. Hirsh, R. Jay, C. Carter, C. England, M. Gent, A. G. Turpie, D. McLaughlin, P. Dodd, M. Thomas, G. Rascob, and P. Ockelford, Different intensities of anticoagulation in the long-term treatment of proximal venous thrombosis, N. Eng. J. Med. 307:1676–1681 (1982).CrossRefGoogle Scholar
  16. 16.
    J. Koepke, Use of survey validated plasma as a means of prothrombin time standardisation, in: “Standardisation of coagulation assays,” D. Triplett, ed., College of Clinical Pathologists, Skokie, Illinois (1982).Google Scholar
  17. 17.
    S. Sevitt and N. G. Gallagher, Prevention of venous thrombosis and pul- monary embolism in injured patients, Lancet ii:974–980 (1959).Google Scholar
  18. 18.
    J. R. A. Mitchell, Anticoagulants in coronary heart disease, Lancet i: 257–262 (1981).CrossRefGoogle Scholar
  19. 19.
    J. Hilden, K. Iverson, F. Rasschon, and M. Schwarz, Anticoagulants in acute myocardial infarction, Lancet ii:327–331 (1961).CrossRefGoogle Scholar
  20. 20.
    Medical Research Council, Assessment of short-term anticoagulant ad- ministration after cardiac infarction, Br. Med. J. 1:335–342 (1969).CrossRefGoogle Scholar
  21. 21.
    Sixty-Plus Reinfarction Group, A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients with myocardial infarction, Lancet II:989–994 (1981).Google Scholar
  22. 22.
    D. W. Barrit and S. C. Jordan, Anticoagulant drugs in the treatment of thromboembolism, Lancet i:1309–13l2 (1962).Google Scholar
  23. 23.
    R. Hull, T. Delmore, E. Genton, J. Hirsh, M. Gent, D. Sackett, D. McLoughlin, and P. Armstrong, Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis, N. Eng. J. Med. 301:855–858 (1979).CrossRefGoogle Scholar
  24. 24.
    R. Hull, T. Delmore, C. Carter, J. Hirst, E. Genton, M. Gent, J. Turpie, and D. McLoughlin, Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis, N. Eng. J. Med. 306:189–194 (1982).CrossRefGoogle Scholar
  25. 25.
    S. Sevitt and D. Innés, Prothrombin time and Thrombotest in injured patients on prophylactic anticoagulant therapy, Lancet i: 124–130 (1964).CrossRefGoogle Scholar
  26. 26.
    D. A. Taberner, L. Poller, R. W. Burslem, and J. B. Jones, Oral anti- coagulants controlled by British Comparative Thromboplastin versus low-dose heparin prophylaxis of deep vein thrombosis, Br. Med. J. 1:272–274 (1978).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • Leon Poller
    • 1
  1. 1.UK Reference Laboratory for Anticoagulant Reagents & ControlWithington HospitalManchesterUK

Personalised recommendations